A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine

The research and development (R&D) of novel adjuvants is an effective measure for improving the immunogenicity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant protein vaccine. Toward this end, we designed a novel single-stranded RNA-based adjuvant, L2, from the SA...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Dong, An, Chaoqiang, Bai, Yu, Li, Kelei, Liu, Jianyang, Wang, Qian, He, Qian, Song, Ziyang, Zhang, Jialu, Song, Lifang, Cui, Bopei, Mao, Qunying, Jiang, Wei, Liang, Zhenglun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504790/
https://www.ncbi.nlm.nih.gov/pubmed/36146661
http://dx.doi.org/10.3390/v14091854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504790/
https://www.ncbi.nlm.nih.gov/pubmed/36146661
http://dx.doi.org/10.3390/v14091854

Ejemplares similares